This achievement is often compared to the Nobel Prize in biopharmaceutical research and celebrates groundbreaking advancements in diagnosing, treating, and curing diseases.

The PANORAMIC trial, conducted by the Clinical Trials Unit at the Nuffield Department of Primary Care Health Sciences at the University of Oxford, demonstrated the power of innovative, large-scale clinical trials during the COVID-19 pandemic. 

With over 29,000 participants, this trial has been essential in assessing the effectiveness of novel antiviral treatments, providing vital data that have informed patient care globally.

Our contribution to the PANORAMIC trial demonstrates our commitment to increasing the accumulation of knowledge in critical areas of medical research. We have helped accelerate the evaluation of potential COVID-19 treatments in real-world settings by providing the robust, reliable and adaptive infrastructure needed for these platform trials.

Professor Chris Butler and Professor Ly-Mee Yu, co-chief Investigators of the PRINCIPLE and PANORAMIC trials, have highlighted the significance of collaborative research and the agility of the research infrastructure. 

‘The PRINCIPLE and PANORAMIC trials have not only identified effective treatments for COVID-19 but have also showcased the agility and responsiveness of our research infrastructure. These platform and decentralised trial design serves as a model for rapidly evaluating interventions during future pandemics or public health emergencies.’ - Ly-Mee Yu

The recognition from the Prix Galien Foundation signifies the hard work and dedication of everyone involved. It also highlights the significant role of innovative technologies like ours in transforming clinical research. Together, we are shaping a future where rapid, effective responses to health crises are not just possible but essential for improving global health outcomes.

Sources:

Nuffield Department of Primary Care Health Sciences

University of Oxford

Panoramic Trial